Ibrahim A Qaddoumi, MD
Disclosures: Nothing to disclose
OMB No. 0925-0046, Biographical Sketch Format Page

OMB No. 0925-0001 and 0925-0002 (Rev. 09/17 Approved Through 03/31/2020)

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person.  DO NOT EXCEED FIVE PAGES.

NAME: QADDOUMI, Ibrahim Abdel-Rahim

eRA COMMONS USER NAME (credential, e.g., agency login): iqaddoumi

POSITION TITLE: Associate Member

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)

INSTITUTION AND LOCATION

DEGREE

(if applicable)

 

Completion Date

MM/YYYY

 

FIELD OF STUDY

 

Damascus University, Damascus, Syria

 

Al-Basheer Hospital, Amman, Jordan

 

Jordan University Hospital

 

St. Joseph Mercy Hospital/Wayne State University, Pontiac, MI

 

Medical University of South Carolina, Charleston, SC

 

M.D.

 

Internship

 

Residency

 

Residency

 

 

Fellowship

10/1992

 

12/1993

 

6/1995

 

6/1999

 

 

6/2002

Medical

 

Medical

 

Medical

 

Medical

 

 

Medical

Medical University of South Carolina, SC

M.S.

11/2003

Biology

 

A.              Personal Statement

 

In Oncology, my research focuses primarily on low-grade gliomas (LGGs), particularly the aggressive subtypes. One facet of my research program centers on studying novel molecular-targeted therapies to avoid the many chemotherapy regimens that children with LGG require because of multiple recurrences. Another aspect of my research program focuses on improving the quality-of-life (QoL) of patients with LGG. Maintaining a relatively high QoL is important for survivors of LGG because of the generally excellent long-term survival rates for children with LGG. Another important approach to improving quality of life in LGG is by decreasing the diagnostic interval and this can be done through research and education. I am working on an educational initiative that will be implemented at a global level. This will help decrease delayed diagnosis in children with CNS tumors.

 

Approximately 85% of children with cancer reside in developing countries. Another important aspect of my research program is improving the care for this underserved population through a global approach. Integrating telemedicine in these efforts has helped many children around the world, as documented through work by the Global Pediatric Medicine (GPM) department at St. Jude in Central America and the Middle East. In addition to decreasing morbidity and mortality for patients with LGG in developing countries through telemedicine-based initiatives, the potential for increasing research efforts in the developed world is evident, as shown through a GPM initiative undertaken for children with osteosarcoma in Chile. In addition, cancer centers in developing countries can support biologic and genetic research by providing tumor tissues for molecular analyses in retinoblastoma studies. One of my main strengths is building programs and I plan to apply this skill in different countries to help build local capacity to treat brain tumors and retinoblastoma.

 

  1. Hazin R, Qaddoumi I. Teleoncology: current and future applications for improving cancer care globally. Lancet Oncol 11(2):204210, 2010. NIHMSID: NIHMS27975

**This article was well received by the editorial office of Lancet Oncology and was chosen for the cover of that issue.

  1. Qaddoumi I, Bass J, Wu J, Billups C, Wozniak A, Merchant T, Haik T, Wilson M, Rodriguez-Galindo C. Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol 30(10):103441, 2012. PMCID: PMC3341147

**This article received an editorial by A. Leahey and a commentary by G. Veal and was considered by Reuters as newsworthy and selected for a news story.

3.               Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, Tang B, Orisme W, Punchihewa C, Parker M, Qaddoumi I, Boop FA, Lu C, Kandoth C, Ding L, Lee R, Huether R, Chen X, Hedlund E, Nagahawatte P, Rusch M, Boggs K, Cheng J, Becksfort J, Ma J, Song G, Li Y, Wei L, Wang J, Shurtleff S, Easton J, Zhao D, Fulton RS, Fulton LL, Dooling DJ, Vadodaria B, Mulder HL, Tang C, Ochoa K, Mullighan CG, Gajjar A, Kriwacki R, Sheer D, Gilbertson RJ, Mardis ER, Wilson RK, Downing JR, Baker SJ, Ellison DW. St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project. Nat Genet 45(6):602612, 2013. Epub 2013 Apr 14. NIHMSID: NIHMS474986

4.               Qaddoumi I, Orisme W, Wen J, Santiago T, Gupta K, Dalton JD, Tang B, Haupfear K, Punchihewa C, Easton J, Mulder H, Boggs K, Shao Y, Rusch M, Becksfort J, Gupta P, Wang S, Lee RP, Brat D, Peter Collins V, Dahiya S, George D, Konomos W, Kurian KM, McFadden K, Serafini LN, Nickols H, Perry A, Shurtleff S, Gajjar A, Boop FA, Klimo PD Jr, Mardis ER, Wilson RK, Baker SJ, Zhang J, Wu G, Downing JR, Tatevossian RG, Ellison DW. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta Neuropathol. 2016 Jan 25. PMID: 26810070.

 

B.              Positions and Honors

 

Positions:

 

20022007              Consultant Pediatric Hematology-Oncology, King Hussein Cancer Center, Amman, Jordan

20022007              Head, Pediatric Neuro-Oncology, King Hussein Cancer Center, Amman, Jordan

20032005              Co-Director, KHCC Joint Adult and Pediatric Neuro-Oncology Program, Amman, Jordan

20032007              Head, Pediatric Ocular Oncology, King Hussein Cancer Center, Amman, Jordan

20062007              Head, KHCC Telemedicine Committee, Amman, Jordan

20072010              Assistant Member, Department of Oncology, St. Jude Children’s Research Hospital,

              Memphis, TN

2010present              Associate Member, Department of Oncology, St. Jude Children’s Research Hospital,

              Memphis, TN

 

Honors:

1994              General Jordanian Internship Exam, Ranked 1st

1995              Resident of the Year Award, Combined Medicine & Pediatrics Program

2018                                          St. Jude Patient Family-Centered Care Champion Award

 

C.              Contribution to Science

 

1.               My early publications in Jordan demonstrated that complex childhood cancers, such as brain tumors and retinoblastoma, can be cured in developing countries. We showed that through twining, telemedicine, protocol-based therapy, empowering nursing, and team approaches that survival rates equivalent to those of advanced countries can be achieved within a short period.

 

a.              Qaddoumi I, Mansour A, Musharbash A, Drake J, Swaidan M, Tihan T, Bouffet E. Impact of telemedicine on pediatric neurooncology in a developing country: The Jordanian Canadian Experience. Pediatr Blood Cancer 48(1):3943, 2007.

b.               Qaddoumi I, Musharbash A, Elayyan M, Mansour A, Al-Hussaini M, Drake J, Swaidan M, Bartels U, Bouffet E. Closing the survival gap: implementation of medulloblastoma protocols in a low-income country through a twinning program. Int J Cancer 122(6):12031206, 2008.

c.               Qaddoumi I, Nawaiseh I, Mehyar M, Razzouk B, Haik BG, Kharma S, Jaradat I, Rodriguez-Galindo C, Wilson MW. Team management, twinning, and telemedicine in retinoblastoma: A 3-tier approach implemented in the first eye salvage program in Jordan. Pediatr Blood Cancer 51(2):241244, 2008.

**This article received commentary by AT Meadows.

d.              Al-Qudimat MR, Day S, Almomani T, Odeh D, Qaddoumi I. Clinical nurse coordinators: a new generation of highly specialized oncology nursing in Jordan. J Pediatr Hematol Oncol 31(1):3841, 2009.

 

2.               During my fellowship, I became a strong believer in the importance of maintaining QoL for patients and that cures at any cost” should not be the only goal of physicians. In addition to preserving the QoL of my patients, I believe it is important to implement interventions that prevent, ameliorate, or reverse the late effects that occur in survivors of childhood cancers. While in Jordan, my team launched the first low-vision clinic service at the King Hussein Cancer Center (KHCC) in Amman, Jordan and helped start a low-visioncertified course at the German Jordanian University.

                            http://www.masterstudies.com/M.Sc.-in-Vision-Rehabilitation/Jordan/German-Jordanian-University- (GJU)/

 

a.               Qaddoumi I, Ellison DW, Morris EB, Broniscer A, Boop F, Merchant T, Palmer SL, Gajjar A. Dysembryoplastic neuroepithelial tumors and cognitive outcome: cure at a price? Cancer 116(23):54615469, 2010. PMCID: PMC3556450

b.               Qaddoumi I, Carey SS, Conklin H, Jenkins J, Sabin N, Boop F, Pai-Panandiker A, Baker J, Wright K, Broniscer A, Gajjar A. Characterization, treatment, and outcome of intracranial neoplasms in the first 120 days of life. J Child Neurol 26(8):988994, 2011. PMCID: PMC3174527 NIHMS318186

c.               Qaddoumi I, Bass J, Wu J, Billups C, Wozniak A, Merchant T, Haik T, Wilson M, Rodriguez-Galindo C. Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol 30(10):10341041, 2012. PMCID: PMC3341147.

**This article was well received by the editorial office of J Clin Oncol and was selected for an editorial by A Leahey for that issue. In addition, it received a commentary by G Veal and was considered by Reuters as news worthy and was selected for a news story.

d.               Willard VW, Qaddoumi I, Chen S, Zhang H, Brennan R, Rodriguez-Galindo C, Wilson MW, Phipps S. Developmental and adaptive functioning in children with retinoblastoma: a longitudinal investigation. J Clin Oncol 32(25):27882793, 2014. PMID: 25024069

 

3.              As a member of the GPM team at St. Jude Children’s Research Hospital (St. Jude), I have continued to promote telemedicine as a successful strategy to improve childhood cancer in developing countries and demonstrate its effects on outcome, building local capacity, saving time and money, and providing timely second opinions.

 

a.               Hazin R, Qaddoumi I. Teleoncology: current and future applications for improving cancer care globally. Lancet Oncol 11(2):204210, 2010. NIHMSID: NIHMS27975 **This article was well received by the editorial office of Lancet Oncology and was chosen for cover of that issue,

b.              Qaddoumi I, Ribeiro RC. Can communication technologies reduce inequalities in cancer care? Lancet Oncol 12(3):224, 2011.

c.               Santiago T, Jenkins J, Pedrosa F, Billups C, Quintana Y, Ribeiro R, Qaddoumi I. Improving the histopathologic diagnosis of pediatric malignancies in a low-resource setting by combining focused training and telepathology strategies. Pediatr Blood Cancer 59(2):221225, 2012. PMCID: 22315236

              **This article received commentary by D Schmidt.

d.              Alfaar AS, Kamal S, Abouelnaga S, Greene WL, Qintana Y, Ribeiro RC, Qaddoumi I. International telepharmacy education: another venue to improve cancer care in the developing world. Telemed J E Health 18(6):470474, 2012. Epub 2012 Jun 5. PMCID: PMC3399109

 

4.               As a faculty member in the neuro-oncology program, I continue to improve our understanding of the biology, genetics, late effects, and clinical issues associated with gliomas, especially low-grade types.

 

a.              Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, Tang B, Orisme W, Punchihewa C, Parker M, Qaddoumi I, Boop FA, Lu C, Kandoth C, Ding L, Lee R, Huether R, Chen X, Hedlund E, Nagahawatte P, Rusch M, Boggs K, Cheng J, Becksfort J, Ma J, Song G, Li Y, Wei L, Wang J, Shurtleff S, Easton J, Zhao D, Fulton RS, Fulton LL, Dooling DJ, Vadodaria B, Mulder HL, Tang C, Ochoa K, Mullighan CG, Gajjar A, Kriwacki R, Sheer D, Gilbertson RJ, Mardis ER, Wilson RK, Downing JR, Baker SJ, Ellison DW. St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project. Nat Genet 45(6):602612, 2013. Epub 2013 Apr 14. NIHMSID: NIHMS474986

b.               Upadhyaya SA, Ghazwani Y, Wu S, Broniscer A, Boop FA, Gajjar A, Qaddoumi I. Mortality in children with low-grade glioma or glioneuronal tumors: a single-institution study. Pediatr Blood Cancer 65(1), 2018. PMID: 28708330

c.               Arnautovic A, Billups C, Broniscer A, Gajjar A, Boop F, Qaddoumi I. Delayed diagnosis of childhood low-grade glioma: causes, consequences, and potential solutions. Childs Nerv Syst 2015 Mar 6. PMID: 25742877

d.               Qaddoumi I, Orisme W, Wen J, Santiago T, Gupta K, Dalton JD, Tang B, Haupfear K, Punchihewa C, Easton J, Mulder H, Boggs K, Shao Y, Rusch M, Becksfort J, Gupta P, Wang S, Lee RP, Brat D, Peter Collins V, Dahiya S, George D, Konomos W, Kurian KM, McFadden K, Serafini LN, Nickols H, Perry A, Shurtleff S, Gajjar A, Boop FA, Klimo PD Jr, Mardis ER, Wilson RK, Baker SJ, Zhang J, Wu G, Downing JR, Tatevossian RG, Ellison DW. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta Neuropathol 131(6):833–845, 2016. PMID: 26810070

**This article was well received: It was in the top 5% of all research outputs scored by Altmetric. It was mentioned by 5 news outlets, as well as on Twitter and Google+.

 

5.              As a member of the retinoblastoma team, I continue to promote research and clinical practice in this field by implementing new therapies, reducing treatment burden, and studying the late effects of therapy.

 

a.              Qaddoumi I, Billups CA, Tagen M, Stewart CF, Wu J, Helton K, McCarville MB, Merchant TE, Brennan R, Free TM, Given V, Haik BG, Rodriguez-Galindo C, Wilson MW. Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity. Cancer 118(22):5663-5670, 2012. NIHMSID: NIHMS364863

                            **This article was considered by Reuters as news worthy and was selected for a news story.

b.               Kirzhner M, Shildkrot Y, Haik BG, Qaddoumi I, Rodriguez-Galindo C, Watson MW. Pediatric anophthalmic sockets and orbital implants: outcomes with polymer-coated implants. Ophthalmology 120(6):1300-1304, 2013. PMID: 23399376

c.              Sullivan EM, Wilson MW, Billups CA, Wu J, Merchant TE, Brennan RC, Haik BG, Shulkin B, Free TM, Given V, Rodriguez-Galindo C, Qaddoumi I. Pathologic risk-based adjuvant chemotherapy for unilateral retinoblastoma following enucleation. J Pediatr Hematol Oncol 36(6):e335340, 2014. PMCID: PMC4108566

d.              Brennan RC, Qaddoumi I, Mao S, Wu J, Billups CA, Stewart CF, Hoehn ME, Rodriguez-Galindo C, Wilson MW. Ocular salvage and vision preservation using a topotecan-based regimen for advanced intraocular retinoblastoma. J Clin Oncol 35(1):72–77, 2017. PMID: 28034080

 

Complete List of Published Work in MyBibliography (or SciENcv):

https://www.ncbi.nlm.nih.gov/sites/myncbi/1TOg7Rlg05I/bibliography/45940478/public/?sort=date&direction=descending

 

D.              Additional Information: Research Support and/or Scholastic Performance

 

Active

 

PBTC, PT REIMBURSEMENT (YR 16) (Robinson)

04/01/2014–03/31/2019

NCI

 

Pediatric Brain Tumor Consortium (Patient Reimb YR 16)

 

Reimbursement for PBTC Patient Accrual and Scientific Leadership

 

             

PNOC-1 - PLGA (150751010) (Gajjar)

12/01/201311/30/2018

PLGA FOUNDATION

 

PNOC: Pacific Pediatric Neuro-Oncology Consortium (PLGA)

 

To provide funding for subject enrollments in Pacific Pediatric Neuro-Oncology Consortium (PNOC) clinical trials

 

 

 

Inactive

 

Monaco (YR 5) (Qaddoumi)

01/01/2010–01/31/2016

MONACO, STATE OF

 

Treatment of Children and Young Adults with Acute Myeloid Leukemia-YR 5

 

 

5 U01CA081457-15 PBTC-Boyett (Broniscer)

04/04/2002–03/31/2014

NCI

 

PBTC YR 15

 

Provide support for continued PBTC participation

 

 

5 P01CA023099-32 P5 (Santana)

09/18/2007–07/31/2012

NCI